Entranced98 (talk | contribs) Importing Wikidata short description: "Pharmaceutical drug" Tag: Shortdesc helper |
no longer a stub |
||
(7 intermediate revisions by 5 users not shown) | |||
Line 66: | Line 66: | ||
'''Olsalazine''' is an anti-inflammatory medication used in the treatment of [[ulcerative colitis]].<ref name="pmid2131213">{{cite journal | vauthors = | title = Olsalazine--a further choice in ulcerative colitis | journal = Drug and Therapeutics Bulletin | volume = 28 | issue = 15 | pages = 57–8 | date = July 1990 | pmid = 2131213 | doi = 10.1136/dtb.28.15.57 | s2cid = 7178709 }}</ref><ref name="pmid1711964">{{cite journal | vauthors = Wadworth AN, Fitton A | title = Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease | journal = Drugs | volume = 41 | issue = 4 | pages = 647–64 | date = April 1991 | pmid = 1711964 | doi = 10.2165/00003495-199141040-00009 | s2cid = 243654426 }}</ref> It is sold under the brand name '''Dipentum'''.<ref name=Med1>{{cite web |title=Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc) |url=https://www.medicines.org.uk/emc/product/3708/smpc#gref |website=www.medicines.org.uk |access-date=9 January 2021}}</ref> |
'''Olsalazine''' is an anti-inflammatory medication used in the treatment of [[ulcerative colitis]].<ref name="pmid2131213">{{cite journal | vauthors = | title = Olsalazine--a further choice in ulcerative colitis | journal = Drug and Therapeutics Bulletin | volume = 28 | issue = 15 | pages = 57–8 | date = July 1990 | pmid = 2131213 | doi = 10.1136/dtb.28.15.57 | s2cid = 7178709 }}</ref><ref name="pmid1711964">{{cite journal | vauthors = Wadworth AN, Fitton A | title = Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease | journal = Drugs | volume = 41 | issue = 4 | pages = 647–64 | date = April 1991 | pmid = 1711964 | doi = 10.2165/00003495-199141040-00009 | s2cid = 243654426 }}</ref> It is sold under the brand name '''Dipentum'''.<ref name=Med1>{{cite web |title=Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc) |url=https://www.medicines.org.uk/emc/product/3708/smpc#gref |website=www.medicines.org.uk |access-date=9 January 2021}}</ref> |
||
Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.<ref name=Med1/> |
Olsalazine itself is a pro-drug of [[mesalazine]] (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by [[azoreductases]] produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.<ref name=Med1/> |
||
==History== |
==History== |
||
Line 79: | Line 79: | ||
== References == |
== References == |
||
{{reflist}} |
{{reflist}} |
||
== External links == |
|||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/olsalazine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Olsalazine }} |
|||
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} |
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} |
||
Line 87: | Line 84: | ||
[[Category:Gastroenterology]] |
[[Category:Gastroenterology]] |
||
[[Category: |
[[Category:Hydrazones]] |
||
[[Category:Salicylic acids]] |
[[Category:Salicylic acids]] |
||
{{gastrointestinal-drug-stub}} |
Latest revision as of 15:41, 12 April 2024
Clinical data | |
---|---|
Trade names | Dipentum |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601088 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99% |
Elimination half-life | 0.9 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.116.494 |
Chemical and physical data | |
Formula | C14H10N2O6 |
Molar mass | 302.242 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis.[2][3] It is sold under the brand name Dipentum.[4]
Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.[4]
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Research
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.[5]
References
- ^ a b "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
- ^ "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin. 28 (15): 57–8. July 1990. doi:10.1136/dtb.28.15.57. PMID 2131213. S2CID 7178709.
- ^ Wadworth AN, Fitton A (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs. 41 (4): 647–64. doi:10.2165/00003495-199141040-00009. PMID 1711964. S2CID 243654426.
- ^ a b "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.
- ^ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Retrieved 16 January 2021.